Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 127

1.

Consensus statement of the Hellenic and Cypriot Gastric Cancer Study Group on the diagnosis, staging and management of gastric cancer.

Douridas GN, Fountoulakis A, Souglakos J, Gourtsoyianni S, Vini L, Levidou G, Liakakos T, Agalianos C, Dervenis C, Kalogeridi MA, Karavokyros I, Koumarianou A, Kountourakis P, Oikonomopoulos G, Economopoulou P, Sgouros J, Sgouros SN, Stamou K, Triantopoulou C, Zacharoulis D, Gouvas N, Xynos E.

Updates Surg. 2020 Mar;72(1):1-19. doi: 10.1007/s13304-020-00723-8. Epub 2020 Feb 28.

PMID:
32112342
2.

PKM2 expression as biomarker for resistance to oxaliplatin-based chemotherapy in colorectal cancer.

Sfakianaki M, Papadaki C, Tzardi M, Trypaki M, Manolakou S, Messaritakis I, Saridaki Z, Mavroudis D, Georgoulias V, Souglakos J.

Ann Oncol. 2019 Jul;30 Suppl 4:iv21-iv22. doi: 10.1093/annonc/mdz155.080. Epub 2019 Dec 4. No abstract available.

PMID:
32085086
3.

Circulating tumor cell detection and microsatellite instability status in predicting outcomes of advanced CRC patients.

Messaritakis I, Sfakianaki M, Vogiatzoglou K, Koulouridi A, Dimitriou O, Gouvas N, Athanasakis E, Tsiaoussis I, Xynos E, Mavroudis D, Tzardi M, Souglakos J.

Ann Oncol. 2019 Jul;30 Suppl 4:iv21. doi: 10.1093/annonc/mdz155.078. Epub 2019 Dec 4. No abstract available.

PMID:
32085083
4.

Messenger-RNA Expression of Five Gemcitabine Sensitivity-related Genes Predicting Outcome in Advanced-stage Non-small Cell Lung Cancer.

Ioannidis G, Papadaki C, Lagoudaki E, Tzardi M, Trypaki M, Stathopoulos E, Mavroudis D, Georgoulias V, Souglakos J.

Anticancer Res. 2020 Feb;40(2):901-913. doi: 10.21873/anticanres.14023.

PMID:
32014934
5.

Consensus statement of the Hellenic and Cypriot Oesophageal Cancer Study Group on the diagnosis, staging and management of oesophageal cancer.

Fountoulakis A, Souglakos J, Vini L, Douridas GN, Koumarianou A, Kountourakis P, Agalianos C, Alexandrou A, Dervenis C, Gourtsoyianni S, Gouvas N, Kalogeridi MA, Levidou G, Liakakos T, Sgouros J, Sgouros SN, Triantopoulou C, Xynos E.

Updates Surg. 2019 Dec;71(4):599-624. doi: 10.1007/s13304-019-00696-3. Epub 2019 Dec 2.

PMID:
31792842
6.

Role of anabolic agents in colorectal carcinogenesis: Myths and realities (Review).

Krasanakis T, Nikolouzakis TK, Sgantzos M, Mariolis-Sapsakos T, Souglakos J, Spandidos DA, Tsitsimpikou C, Tsatsakis A, Tsiaoussis J.

Oncol Rep. 2019 Dec;42(6):2228-2244. doi: 10.3892/or.2019.7351. Epub 2019 Oct 3.

7.

Oral Bacteria and Intestinal Dysbiosis in Colorectal Cancer.

Koliarakis I, Messaritakis I, Nikolouzakis TK, Hamilos G, Souglakos J, Tsiaoussis J.

Int J Mol Sci. 2019 Aug 25;20(17). pii: E4146. doi: 10.3390/ijms20174146. Review.

8.

Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.

Souglakos J, Boukovinas I, Kakolyris S, Xynogalos S, Ziras N, Athanasiadis A, Androulakis N, Christopoulou A, Vaslamatzis M, Ardavanis A, Emmanouilides C, Bompolaki I, Kourousis C, Makrantonakis P, Christofyllakis C, Athanasiadis E, Kentepozidis N, Karampeazis A, Katopodi U, Anagnosopoulos A, Papadopoulos G, Prinarakis E, Kalisperi A, Mavroudis D, Georgoulias V.

Ann Oncol. 2019 Aug 1;30(8):1304-1310. doi: 10.1093/annonc/mdz193.

PMID:
31228203
9.

MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer.

Matikas A, Souglakos J, Katsaounis P, Kotsakis A, Kouroupakis P, Pantazopoulos N, Kentepozidis N, Nikolaidi A, Messaritakis I, Tzovara I, Hatzidaki D, Prinarakis E, Georgoulias V.

Target Oncol. 2019 Jun;14(3):285-293. doi: 10.1007/s11523-019-00647-3.

PMID:
31203498
10.

Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer.

Sfakianaki M, Papadaki C, Tzardi M, Trypaki M, Alam S, Lagoudaki ED, Messaritakis I, Zoras O, Mavroudis D, Georgoulias V, Souglakos J.

Cancer Res Treat. 2019 Oct;51(4):1518-1526. doi: 10.4143/crt.2019.008. Epub 2019 Mar 20.

11.

Effect of systemic treatment on the micronuclei frequency in the peripheral blood of patients with metastatic colorectal cancer.

Nikolouzakis TK, Stivaktakis PD, Apalaki P, Kalliantasi K, Sapsakos TM, Spandidos DA, Tsatsakis A, Souglakos J, Tsiaoussis J.

Oncol Lett. 2019 Mar;17(3):2703-2712. doi: 10.3892/ol.2019.9895. Epub 2019 Jan 7.

12.

Economic evaluation of trifluridine and tipiracil hydrochloride in the treatment of metastatic colorectal cancer in Greece.

Gourzoulidis G, Maniadakis N, Petrakis D, Souglakos J, Pentheroudakis G, Kourlaba G.

J Comp Eff Res. 2019 Feb;8(3):133-142. doi: 10.2217/cer-2018-0076. Epub 2018 Dec 14.

PMID:
30547679
13.

Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group.

Kentepozidis N, Economopoulou P, Liontos M, Kotsakis A, Boukovinas I, Vardakis N, Kontopodis E, Prinarakis E, Skaltsi T, Souglakos J, Georgoulias V.

Ann Gastroenterol. 2018 Nov-Dec;31(6):698-704. doi: 10.20524/aog.2018.0311. Epub 2018 Sep 14.

14.

Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG).

Asimakopoulou N, Souglakos J, Kentepozidis N, Karampeazis A, Kotsakis A, Ziras N, Makrantonakis P, Prinarakis E, Vamvakas L, Georgoulias V; Hellenic Oncology Research Group.

J Geriatr Oncol. 2019 Jan;10(1):143-148. doi: 10.1016/j.jgo.2018.08.002. Epub 2018 Oct 23.

PMID:
30366852
15.

Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer.

Messaritakis I, Sfakianaki M, Papadaki C, Koulouridi A, Vardakis N, Koinis F, Hatzidaki D, Georgoulia N, Kladi A, Kotsakis A, Souglakos J, Georgoulias V.

Cancer Chemother Pharmacol. 2018 Nov;82(5):767-775. doi: 10.1007/s00280-018-3666-9. Epub 2018 Aug 9.

PMID:
30094617
16.

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.

Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M.

Eur J Cancer. 2018 Sep;100:35-45. doi: 10.1016/j.ejca.2018.05.010. Epub 2018 Jun 22.

PMID:
29936065
17.

Evaluation of the detection of Toll-like receptors (TLRs) in cancer development and progression in patients with colorectal cancer.

Messaritakis I, Stogiannitsi M, Koulouridi A, Sfakianaki M, Voutsina A, Sotiriou A, Athanasakis E, Xynos E, Mavroudis D, Tzardi M, Souglakos J.

PLoS One. 2018 Jun 8;13(6):e0197327. doi: 10.1371/journal.pone.0197327. eCollection 2018.

18.

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.

Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, Vernerey D, Yamanaka T, Boukovinas I, Meyers JP, Renfro LA, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent DJ, Andre T, Iveson T.

N Engl J Med. 2018 Mar 29;378(13):1177-1188. doi: 10.1056/NEJMoa1713709.

19.

Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis.

Koch C, Schwing AM, Herrmann E, Borner M, Diaz-Rubio E, Dotan E, Feliu J, Okita N, Souglakos J, Arkenau HT, Porschen R, Koopman M, Punt CJA, de Gramont A, Tournigand C, Zeuzem S, Trojan J.

Oncotarget. 2017 Dec 20;9(12):10272-10283. doi: 10.18632/oncotarget.23475. eCollection 2018 Feb 13.

20.

Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer.

Tryfonidis K, Papadaki C, Assele S, Lagoudaki E, Menis J, Koutsopoulos A, Trypaki M, Tsakalaki E, Sfakianaki M, Hasan B, Stathopoulos E, Georgoulias V, Souglakos J.

Pharmacogenomics J. 2019 Feb;19(1):15-24. doi: 10.1038/s41397-018-0013-9. Epub 2018 Feb 22.

PMID:
29472587

Supplemental Content

Loading ...
Support Center